Modular Regulatory Strategy Creates Defined Milestone Cadence, Enables Earlier FDA Engagement, and S...
News Room
Termination Reflects Company's Confidence in Current Capital Position
White Bear Lake, Minnesota--(Newsfile Corp. - June 18, 2026) -Envoy Medical® Inc. (NASDAQ: COCH) ("E...
White Bear Lake, Minnesota--(Newsfile Corp. - June 4, 2026) -Envoy Medical® Inc. (NASDAQ: COCH), a h...
Australian and European Patent Offices Grant the Company Four Patents Relating to Key Innovations in...
Company Completes Historic Trial Enrollment, Secures Transformational Financing, and Sees Promising ...
Positive Initial 6-Month Data from First 10 Patients and Improvements in Speech Understanding and Qu...
All 56 Enrolled Subjects Have Been Through Their Activation Visit Firming Up Study Timeline
Proven Med Tech Leader with an Established Track Record of Commercial Success and Optimizing Shareho...
Company Remains on Schedule for PMA Submission to FDA White Bear Lake, Minnesota--(Newsfile Corp. - ...
*The materials and resources presented are intended to be an educational resource for general purposes only. They are not intended to constitute medical or business advice or in any way replace the independent medical judgment of a trained and licensed physician. Each person’s situation is unique and risks, outcomes, experience and results may vary. CAUTION: The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by federal (or United States) law to investigational use.










